Although the median cholecalciferol supplementation dose in our Crohn’s disease cohort was lower (1000 IU per day), considering the background of the dramatic induction observed in the aforementioned trial, we speculate that oral cholecalciferol intake may still have a substantial impact on VD receptor expression and VD receptor-dependent signaling, including the CCL20 downregulation. This evidence concerns the gene CCL20 and Crohn disease.